HRP20230775T1 - Genska terapija za poboljšanje vida - Google Patents
Genska terapija za poboljšanje vida Download PDFInfo
- Publication number
- HRP20230775T1 HRP20230775T1 HRP20230775TT HRP20230775T HRP20230775T1 HR P20230775 T1 HRP20230775 T1 HR P20230775T1 HR P20230775T T HRP20230775T T HR P20230775TT HR P20230775 T HRP20230775 T HR P20230775T HR P20230775 T1 HRP20230775 T1 HR P20230775T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- aav vector
- rod
- macular degeneration
- vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201503008A GB201503008D0 (en) | 2015-02-23 | 2015-02-23 | Treatment |
| PCT/GB2016/050419 WO2016135457A1 (en) | 2015-02-23 | 2016-02-19 | Gene therapy to improve vision |
| EP16706413.8A EP3261679B1 (en) | 2015-02-23 | 2016-02-19 | Gene therapy to improve vision |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230775T1 true HRP20230775T1 (hr) | 2023-10-27 |
Family
ID=52822045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230775TT HRP20230775T1 (hr) | 2015-02-23 | 2016-02-19 | Genska terapija za poboljšanje vida |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20180030477A1 (enExample) |
| EP (1) | EP3261679B1 (enExample) |
| JP (1) | JP6771474B2 (enExample) |
| KR (1) | KR102272466B1 (enExample) |
| CN (1) | CN107530449A (enExample) |
| AU (2) | AU2016225277B2 (enExample) |
| CA (1) | CA2977464C (enExample) |
| CY (1) | CY1126098T1 (enExample) |
| DK (1) | DK3261679T3 (enExample) |
| EA (1) | EA201791900A1 (enExample) |
| ES (1) | ES2947308T3 (enExample) |
| FI (1) | FI3261679T3 (enExample) |
| GB (1) | GB201503008D0 (enExample) |
| HK (1) | HK1248594A1 (enExample) |
| HR (1) | HRP20230775T1 (enExample) |
| HU (1) | HUE062319T2 (enExample) |
| IL (1) | IL254066B (enExample) |
| LT (1) | LT3261679T (enExample) |
| MX (1) | MX2017010772A (enExample) |
| MY (1) | MY186444A (enExample) |
| PH (1) | PH12017501525B1 (enExample) |
| PL (1) | PL3261679T3 (enExample) |
| PT (1) | PT3261679T (enExample) |
| RS (1) | RS64372B1 (enExample) |
| SG (2) | SG11201706822XA (enExample) |
| SI (1) | SI3261679T1 (enExample) |
| SM (1) | SMT202300200T1 (enExample) |
| WO (1) | WO2016135457A1 (enExample) |
| ZA (1) | ZA201706440B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3037436A1 (en) * | 2016-09-22 | 2018-03-29 | Sorbonne Universite | Optogenetically transformed photoreceptor precursor cells for the use in the treatment of retinal degenerative diseases |
| WO2023280388A1 (en) * | 2021-07-06 | 2023-01-12 | Institute Of Molecular And Clinical Ophthalmology Basel | Promoter for specific expression of genes in rod photoreceptors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2442670A1 (en) * | 2001-04-13 | 2002-10-24 | The Trustees Of The University Of Pennsylvania | Method of treating or retarding the development of blindness |
| CA2685900A1 (en) * | 2006-05-04 | 2007-11-15 | Wayne State University | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids |
| MX2010011467A (es) * | 2008-04-18 | 2011-02-15 | Novartis Forschungsstiftung | Novedosas herramientas y metodos terapeuticos para tratar la ceguera. |
| GB2498325B (en) * | 2010-10-15 | 2018-05-02 | Eos Neuroscience Inc | Engineered human GRM6 enhancer sequence for use in eye therapies |
| US8957028B2 (en) * | 2010-11-13 | 2015-02-17 | Massachusetts Institute Of Technology | Red-shifted opsin molecules and uses thereof |
| WO2012167109A2 (en) * | 2011-06-03 | 2012-12-06 | Massachusetts Eye & Ear Infirmary | Rpgrip1 gene therapy for leber congenital amaurosis |
| WO2013124477A1 (en) * | 2012-02-24 | 2013-08-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of retinal degenerative diseases |
| AU2015296502A1 (en) * | 2014-07-29 | 2017-02-23 | Circuit Therapeutics, Inc. | System and method for optogenetic therapy |
-
2015
- 2015-02-23 GB GB201503008A patent/GB201503008D0/en not_active Ceased
-
2016
- 2016-02-19 MY MYPI2017001247A patent/MY186444A/en unknown
- 2016-02-19 SG SG11201706822XA patent/SG11201706822XA/en unknown
- 2016-02-19 RS RS20230560A patent/RS64372B1/sr unknown
- 2016-02-19 SI SI201631710T patent/SI3261679T1/sl unknown
- 2016-02-19 EP EP16706413.8A patent/EP3261679B1/en active Active
- 2016-02-19 PH PH1/2017/501525A patent/PH12017501525B1/en unknown
- 2016-02-19 HU HUE16706413A patent/HUE062319T2/hu unknown
- 2016-02-19 HR HRP20230775TT patent/HRP20230775T1/hr unknown
- 2016-02-19 CN CN201680023264.6A patent/CN107530449A/zh active Pending
- 2016-02-19 HK HK18108485.5A patent/HK1248594A1/zh unknown
- 2016-02-19 DK DK16706413.8T patent/DK3261679T3/da active
- 2016-02-19 WO PCT/GB2016/050419 patent/WO2016135457A1/en not_active Ceased
- 2016-02-19 ES ES16706413T patent/ES2947308T3/es active Active
- 2016-02-19 FI FIEP16706413.8T patent/FI3261679T3/fi active
- 2016-02-19 CA CA2977464A patent/CA2977464C/en active Active
- 2016-02-19 PT PT167064138T patent/PT3261679T/pt unknown
- 2016-02-19 US US15/552,737 patent/US20180030477A1/en not_active Abandoned
- 2016-02-19 AU AU2016225277A patent/AU2016225277B2/en active Active
- 2016-02-19 EA EA201791900A patent/EA201791900A1/ru unknown
- 2016-02-19 PL PL16706413.8T patent/PL3261679T3/pl unknown
- 2016-02-19 SG SG10202005923WA patent/SG10202005923WA/en unknown
- 2016-02-19 LT LTEPPCT/GB2016/050419T patent/LT3261679T/lt unknown
- 2016-02-19 KR KR1020177026938A patent/KR102272466B1/ko active Active
- 2016-02-19 MX MX2017010772A patent/MX2017010772A/es unknown
- 2016-02-19 SM SM20230200T patent/SMT202300200T1/it unknown
- 2016-02-19 JP JP2017544639A patent/JP6771474B2/ja active Active
-
2017
- 2017-08-20 IL IL254066A patent/IL254066B/en unknown
- 2017-09-22 ZA ZA2017/06440A patent/ZA201706440B/en unknown
-
2020
- 2020-02-21 US US16/797,527 patent/US20200377907A1/en not_active Abandoned
-
2022
- 2022-03-07 AU AU2022201553A patent/AU2022201553B2/en active Active
-
2023
- 2023-07-21 CY CY20231100352T patent/CY1126098T1/el unknown
-
2025
- 2025-06-04 US US19/228,304 patent/US20250290096A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017006652A (es) | Vectores de virus adeno-asociado (aav) dirigidos al sistema nervioso central. | |
| MX2020001997A (es) | Variantes de capside de virus adenoasociado y metodos de uso de estas. | |
| Redinbaugh et al. | Control of virus diseases in maize | |
| WO2015158749A3 (de) | Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark | |
| WO2015168666A3 (en) | Aav vectors for retinal and cns gene therapy | |
| WO2015143418A3 (en) | Gene therapy for retinitis pigmentosa | |
| PH12018502387A1 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| PH12018501055A1 (en) | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders | |
| NZ704275A (en) | Aav-mediated gene therapy for rpgr x-linked retinal degeneration | |
| HUE051953T2 (hu) | Idõskori makula degeneráció kezelése AAV2 variáns és aflibercept alkalmazásával | |
| WO2017044857A3 (en) | Methods and compositions for the treatment of glaucoma | |
| SG10201902285SA (en) | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma | |
| HRP20230775T1 (hr) | Genska terapija za poboljšanje vida | |
| SG11201704919SA (en) | Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav) | |
| EP3372249C0 (en) | AAV/UPR-PLUS VIRUS, UPR-PLUS FUSION PROTEIN, GENETIC TREATMENT METHOD AND ITS USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS, AMONG OTHERS, PARKINSON'S DISEASE AND HUNTINGTON'S DISEASE | |
| JP2018506982A5 (enExample) | ||
| Guillaume-Czitrom et al. | Biologic targeted therapies in pediatric rheumatology | |
| Smetanina et al. | Ekspressiya genov OXA1L i BCS1L, opredelyayushchikh metabolizm atf, zadeystvovannykh v patogeneze varikoznoy bolezni ven, kletkami venoznoy stenki | |
| RU2015131656A (ru) | Способ хемогенетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции астроцитов и нейронов | |
| Ярош et al. | INteRNatIoNal JouRNal oF eXpeRIMeNtal educatIoN № 3, 2015 | |
| EP3305901A4 (en) | Optimized nucleotide sequence and pharmaceutical composition based thereon with prolonged vegf transgene expression | |
| WO2014144815A3 (en) | Vectors and methods to treat ischemia | |
| JP2017025008A5 (enExample) | ||
| EP4048321A4 (en) | ADENO-ASSOCIATED VIRUS (AAV) VECTORS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES AND DISORDERS | |
| 亀井大悟 | Comparison between consecutive and intermittent steroid pulse therapy combined with tonsillectomy for clinical remission of IgA nephropathy |